Eye check advised before starting T2 drug semaglutide
A small potential increased risk of retinopathy worsening after one year for those with Type 2 diabetes following injections of the GLP-1 agonist semaglutide does
A small potential increased risk of retinopathy worsening after one year for those with Type 2 diabetes following injections of the GLP-1 agonist semaglutide does
Novo Nordisk Novo Nordisk has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA)